This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ICUI Stock Gains Following Latest FDA Approvals for Precision IV Pumps
by Zacks Equity Research
ICU Medical aims to enable healthcare systems to customize infusion setups, optimizing device footprint without compromising performance or safety.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.
Danaher Gains From Strength in the Diagnostics Unit Amid Headwinds
by Zacks Equity Research
DHR is poised to gain from strength in the clinical diagnostics business, the Abcam buyout and shareholder-friendly policies. Softness in Life Sciences and Biotechnology units remains a concern.
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues
by Ritujay Ghosh
Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM continues to raise investor optimism due to its strong product portfolio.
MCK Stock Gains as PRISM Acquisition Adds High-Growth Business
by Zacks Equity Research
McKesson acquires 80% ownership in PRISM Vision Holdings, diversifying its business into the high-growth area of ophthalmology. The deal is to be accretive this year.
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.
AVNS Stock Gains Following Direct Sales Deal for MIC-KEY in the UK
by Zacks Equity Research
Avanos takes direct control of MIC-KEY sales in the UK, enhancing market presence, customer engagement and service efficiency, starting July 2025.
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst
by Zacks Equity Research
Milestone Pharmaceuticals faces an FDA setback for its PSVT nasal spray. The company coordinates with regulatory authorities to resolve CRL issues.
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
by Zacks Equity Research
RVTY's strong product portfolio raises optimism about the stock.
GEHC Stock Gains Following Buyout Completion to Boost Its PDx Arm
by Zacks Equity Research
GE HealthCare aims to expand its existing footprint and offerings in Japan, as well as enhance patient access to next-generation radiopharmaceuticals via its latest acquisition.
10 Stocks of the S&P 500 ETF Up More Than 20% in Q1
by Sweta Killa
While many stocks in the S&P 500 ETF posted dismal performance in the just-concluded quarter, we discuss some that rose by more than 20%.
Beat the Market the Zacks Way: Amgen, Stride, Sea Limited in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
by Zacks Equity Research
Merit Medical's strong product portfolio raises optimism about the stock.
Cencora (COR) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Industry Outlook Highlights Cencora, Doximity and Pediatrix Medical
by Zacks Equity Research
Cencora, Doximity and Pediatrix Medical are part of the Zacks Industry Outlook article.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
by Zacks Equity Research
OPK's growth is fueled by Rayaldee's success and promising pipeline progress. However, margin pressure and overdependence on its lead product are concerning.
3 Medical Services Industry Stocks to Buy as AI Fuels Growth
by Urmimala Biswas
The Zacks Medical - Services industry is undergoing a transformation on massive artificial intelligence adoption. COR, DOCS and MD are set to gain the most. Healthcare staffing shortages are leading to an increase in labor wages.
Cencora (COR) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CAH Stock Rises More Than 13% YTD: Should You Buy, Hold or Sell?
by Zacks Equity Research
Cardinal Health's recent acquisitions and GMPD recovery look promising. However, the loss of the Optum Rx contract and margin pressure are likely to hurt short-term prospects.
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval
by Zacks Equity Research
DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The company response is inadequate.
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor
by Zacks Equity Research
DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost competitive advantage.
BDX Stock Declines Following Class I Classification for Alaris Recall
by Zacks Equity Research
BD's recall of Alaris infusion pumps following software issues has been classified as the most severe recall by the FDA. A suspension of sales may hurt the top line going forward.
GEHC Stock Falls Despite New Launch to Boost Breast Cancer Diagnosis
by Zacks Equity Research
GE HealthCare aims to deliver optimal outcomes with its innovative, patient-friendly and efficient AI-driven technology via its latest product offering.